Adoke, Yeka http://orcid.org/0000-0002-2899-1470
Zoleko-Manego, Rella
Ouoba, Serge
Tiono, Alfred B.
Kaguthi, Grace
Bonzela, Juvêncio Eduardo
Duong, Tran Thanh
Nahum, Alain
Bouyou-Akotet, Marielle
Ogutu, Bernhards
Ouedraogo, Alphonse
Macintyre, Fiona
Jessel, Andreas
Laurijssens, Bart
Cherkaoui-Rbati, Mohammed H.
Cantalloube, Cathy
Marrast, Anne Claire
Bejuit, Raphaël
White, David
Wells, Timothy N. C.
Wartha, Florian
Leroy, Didier
Kibuuka, Afizi
Mombo-Ngoma, Ghyslain
Ouattara, Daouda
Mugenya, Irène
Phuc, Bui Quang
Bohissou, Francis
Mawili-Mboumba, Denise P.
Olewe, Fredrick
Soulama, Issiaka
Tinto, Halidou
Ramharter, Michael
Nahum, Diolinda
Zohou, Hermione
Nzwili, Irène
Ongecha, John Michael
Thompson, Ricardo
Kiwalabye, John
Diarra, Amidou
Coulibaly, Aboubacar S.
Bougouma, Edith C.
Kargougou, Désiré G.
Tegneri, Moubarak
Castin Vuillerme, Catherine
Djeriou, Elhadj
Ansary, Aziz Filali
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria
https://doi.org/10.1186/s12936-021-03749-4
AQ-13 - an investigational antimalarial drug
https://doi.org/10.1080/13543784.2019.1560419
Funding for this research was provided by:
Medicines for Malaria Venture
Sanofi
Article History
Received: 22 January 2021
Accepted: 28 April 2021
First Online: 19 May 2021
Declarations
:
: The study was approved by the relevant IECs and, where relevant, local regulatory authorities at each of the participating sites. The study was conducted at 10 sites across 6 African countries, Benin (Zinvié), Burkina Faso (Nanoro, Banfora and Niangoloko), Gabon (Libreville, Lambaréné), Kenya (Siaya, Kisumu), Mozambique (Chokwe), and Uganda (Tororo), and 4 sites in Vietnam (Binh Phuoc, Gia Lai, Khanh Hoa, Quang tri, although the last 2 sites did not randomize any patient). Participants provided written informed consent prior to inclusion. The local and national IECs that approved the study are the following: Comité National d’Ethique pour la Recherche en Santé, Cotonou, Benin (national IEC). Centre National de la Recherche Scientifique et Technologique (CNRST)—Comité d'Ethique Institutionnel, Bobo-Dioulasso, Burkina Faso (local IEC), Comité d’Ethique pour la Recherche en Santé, Ouagadougou, Burkina Faso (national IEC), Comité Institutionnel de Bioéthique, Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ouagadougou, Burkina Faso (local IEC), Comité National d’Ethique pour la Recherche (CNER), Libreville, Gabon (national IEC), Kenya Medical Research Institute (KEMRI)—Scientific and Ethics Review Unit (SERU), Nairobi, Kenya (local IEC), Ao Comitê Nacional Bioética para a Saúde (CNBS), Maputo, Mozambique (national IEC), Makerere University, College of Health Sciences, School of Biomedical Sciences, Higher Degrees Research and Ethics Committee, Kampala, Uganda (local IEC), Ethics Committee of National Institute of Malariology, Parasitology and Entomology (NIMPE), Ha Noi, Vietnam (local IEC), National Ethics committee in Biomedical Research, Ministry of Health, Vietnam (national IEC).
: Not applicable.
: FM, MHCR, ACM, TW, FW, and DL are employed by MMV. BL is a consultant for MMV and was paid for his work on the FALCI Study. AJ, CC and RB are employed by Sanofi. AJ holds shares in the company. The other authors declare that they have no competing interests.